Loading...
•
Dec 31, 2024
Guardant Health Q4 2024 Earnings Report
Guardant Health reported strong revenue growth and increased testing volumes in Q4 2024.
Key Takeaways
Guardant Health reported Q4 2024 revenue of $201.8 million, a 30% year-over-year increase, driven by strong growth in precision oncology testing. The company reduced net loss compared to the prior year and continued to expand its product portfolio and partnerships.
Total revenue increased by 30% to $201.8 million.
Precision oncology testing revenue rose by 30% to $184.6 million.
Non-GAAP net loss per share improved to $0.62 from $0.64 last year.
Shield screening tests generated $4.1 million in revenue.
Guardant Health
Guardant Health
Guardant Health Revenue by Segment
Revenue by Segment
Oncology Revenue
CapyFin.com Forward Guidance
Guardant Health expects FY 2025 revenue to be between $850 million and $860 million, representing a 15-16% increase year-over-year.
Positive Outlook
- Oncology revenue projected to grow approximately 15%.
- Oncology clinical volume expected to accelerate to 25% growth.
- Screening revenue forecasted between $25 million and $30 million.
- Non-GAAP gross margin expected in the range of 62-63%.
- Free cash flow burn projected to improve to $225-235 million.
Challenges Ahead
- Increased expenses due to Shield commercial ramp-up.
- Operating expenses expected to rise by 8-9% in 2025.
- Continued net losses expected despite revenue growth.
- Screening segment expected to have $200 million in net cash burn.
- Market uncertainties may impact reimbursement rates.